Denali Therapeutics Inc. (DNLI): Price and Financial Metrics


Denali Therapeutics Inc. (DNLI)

Today's Latest Price: $18.74 USD

1.54 (8.95%)

Updated Apr 6 4:00pm

Add DNLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DNLI Stock Summary

  • With a price/sales ratio of 71.53, Denali Therapeutics Inc has a higher such ratio than 98.16% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Denali Therapeutics Inc is reporting a growth rate of 446.26%; that's higher than 96.98% of US stocks.
  • Revenue growth over the past 12 months for Denali Therapeutics Inc comes in at -79.34%, a number that bests merely 1.41% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Denali Therapeutics Inc, a group of peers worth examining would be FATE, BPMC, AGIO, ASMB, and NKTR.
  • Visit DNLI's SEC page to see the company's official filings. To visit the company's web site, go to www.denalitherapeutics.com.
DNLI Daily Price Range
DNLI 52-Week Price Range

DNLI Stock Price Chart More Charts


DNLI Price/Volume Stats

Current price $18.74 52-week high $30.41
Prev. close $17.20 52-week low $12.39
Day low $17.68 Volume 509,382
Day high $18.89 Avg. volume 746,385
50-day MA $20.73 Dividend yield N/A
200-day MA $18.86 Market Cap 1.98B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.


DNLI Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

DNLI Price Returns

1-mo 3.08%
3-mo -0.32%
6-mo 26.54%
1-year -30.82%
3-year N/A
5-year N/A
YTD 7.58%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A
2015 N/A

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6085 seconds.